Abstract
The importance of left ventricular outflow tract obstruction in a large subset of patients with HCM and drug-refractory symptoms, as well as the value of septal reduction therapy (surgical myectomy or alcohol septal ablation), has been demonstrated. However, determining the precise cause of symptoms in the HCM patient, and specifically implicating outflow tract obstructive physiology, can be quite challenging. Accordingly, a detailed and comprehensive morphologic and physiologic evaluation of the HCM patient is of paramount importance to determine which patients may benefit from septal reduction therapy. Patients should be considered for septal reduction therapy when (a) symptoms are clearly and primarily attributed to obstructive HCM despite optimal medical therapy; (b) symptoms encompass severe heart failure or angina (NYHA or CCS class III/IV), recurrent obstruction-related syncope, or recurrent clinical decompensation due to refractory paroxysmal atrial fibrillation; (c) a gradient ≥50 mmHg can be demonstrated on optimal medical therapy; and (d) obstruction is clearly dynamic and subvalvular, resulting mainly from septum-to-anterior mitral leaflet contact. Surgical myectomy has been the traditional gold standard invasive therapy. Alcohol septal ablation (ASA) is a minimally invasive catheter-based alternative with less patient discomfort and more rapid recovery; however, only patients with certain anatomic criteria are candidates. Evidence from nonrandomized studies suggests that ASA and surgical myectomy result in similar short- and long-term outcomes with respect to hemodynamic and functional improvements, with greater propensity for pacemaker placement with septal ablation. Based on comprehensive assessment of clinical symptoms, associated comorbidities, and echocardiographic, electrocardiographic, and angiographic features, some patients are better suited for myectomy, while others are better suited for ASA. This chapter will review indications for septal reduction therapy and how to individualize the selection of the appropriate septal reduction procedure in clinical practice.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Brock RC. Functional obstruction of the left ventricle (acquired aortic subvalvar stenosis). Guys Hosp Rep. 1957;106:221.
Braunwald E, Lambrew CT, Rockoff SD, Ross J Jr, Morrow AG. Idiopathic hypertrophic subaortic stenosis. I. A description of the disease based upon an analysis of 64 patients. Circulation. 1964;29(Suppl 4):3–119.
Wigle ED, Lenkei SC, Chrysohou A, Wilson DR. Muscular subaortic stenosis: the effect of peripheral vasodilatation. Can Med Assoc J. 1963;89:896–9.
Criley JM, Lewis KB, White RI, Ross RS. Pressure gradients without obstruction: a new concept of “hypertrophic subaortic stenosis”. Circulation. 1964;32:881–7.
Maron BJ, Epstein SE. Clinical significance and therapeutic implications of the left ventricular outflow tract pressure gradient in hypertrophic cardiomyopathy. Am J Cardiol. 1986;58:1093–6.
Spirito P, Maron BJ. Patterns of systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy: assessment of two-dimensional echocardiography. Am J Cardiol. 1984;54:1039–46.
Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348:295–303.
Maron MS, Olivotto I, Zenovich AG, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114:2232–9.
Autore C, Bernabò P, Barillà CS, Bruzzi P, Spirito P. The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. J Am Coll Cardiol. 2005;45:1076–80.
Elliott PM, Gimeno JR, Tomé MT, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J. 2006;27:1933–41.
Ommen SR, Maron BJ, Olivotto I, et al. Long term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46:470–6.
Woo A, Williams WG, Choi R, et al. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation. 2005;111:2033–41.
Maron BJ, Dearani JA, Ommen SR, et al. The case for surgery in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;44:2044–53.
Maron BJ, Maron MS, Wigle ED, Braunwald E. The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009;54:191–200.
Spirito P, Maron BJ, Rosing DR. Morphologic determinants of hemodynamic state after ventricular septal myectomy-myectomy in patients with obstructive hypertrophic cardiomyopathy: M-mode and two-dimensional echocardiographic assessment. Circulation. 1984;70:984–95.
Nasseri BA, Stamm C, Siniawski H, Kukucka M, Komoda T, Delmo Walter EM, et al. Combined anterior mitral valve leaflet retention plasty and septal myectomy in patients with hypertrophic obstructive cardiomyopathy. Eur J Cardiothorac Surg. 2011;40:1515–20.
Schulte HD, Bircks WH, Loesse B, Godehardt EA, Schwartzkopff B. Prognosis of patients with hypertrophic obstructive cardiomyopathy after transaortic myectomy. Late results up to 25 years. J Thorac Cardiovasc Surg. 1993;106:709–17.
Robbins RC, Stinson EB. Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg. 1996;11:586–94.
Smedira NG, Lytle BM, Lever HM, Rajeswaran J, Krishnaswamy G, Kaple RK, Dolney DO, Blackstone EH. Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy. Ann Thorac Surg. 2008;85:127–33.
Dearani JA, Ommen SR, Gersh BJ, Schaff HV, Danielson GK. Surgery insight: septal myectomy for obstructive hypertrophic cardiomyopathy—the Mayo Clinic experience. Nat Clin Pract Cardiovasc Med. 2007;4:503–12.
Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995;346:211–4. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation. 1998;98:2415–21.
Lakkis NM, Nagueh SF, Dunn JK, Killip D, Spencer WH 3rd. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up. J Am Coll Cardiol. 2000;36:852–5.
Kim JJ, Lee CW, Park SW, Hong MK, Lim HY, Song JK, Jin YS, Park SJ. Improvement in exercise capacity and exercise blood pressure response after transcoronary alcohol ablation therapy of septal hypertrophy in hypertrophic cardiomyopathy. Am J Cardiol. 1999;83:1220–3.
Chen J, Nagaraj H, Bhambhani P, Kliner DE, Soman P, Garcia EV, et al. Effect of alcohol septal ablation in patients with hypertrophic cardiomyopathy on left-ventricular mechanical dyssynchrony as assessed by phase analysis of gated SPECT myocardial perfusion imaging. Int J Cardiovasc Imaging. 2011;28:1375. https://doi.org/10.1007/s10554-011-9942-y.
Timmer SA, Knaapen P, Germans T, Dijkmans PA, Lubberink M, Ten Berg JM, et al. Effects of alcohol septal ablation on coronary microvascular function and myocardial energetics in hypertrophic obstructive cardiomyopathy. Am J Physiol Heart Circ Physiol. 2011;301:H129–37.
Mazur W, Nagueh SF, Lakkis NM, Middleton KJ, Killip D, Roberts R, Spencer WH 3rd. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation. 2001;103:1492–6.
Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation. 1998;98:2415–21.
Gietzen FH, Leuner CJ, Raute-Kreinsen U, Dellmann A, Hegselmann J, Strunk-Mueller C, Kuhn HJ. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J. 1999;20:1342–54.
Nagueh SF, Lakkis NM, Middleton KJ, Killip D, Zoghbi WA, Quinones MA, Spencer WH 3rd. Changes in left ventricular filling and left atrial function six months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 1999;34:1123–8.
Sitges M, Shiota T, Lever HM, Qin JX, Bauer F, Drinko JK, Agler DA, Martin MG, Greenberg NL, Smedira NG, Lytle BW, Tuzcu EM, Garcia MJ, Thomas JD. Comparison of left ventricular diastolic function in obstructive hypertrophic cardiomyopathy in patients undergoing percutaneous septal alcohol ablation versus surgical myotomy/myectomy. Am J Cardiol. 2003;91:817–21.
Boekstegers P, Steinbigler P, Molnar A, Schwaiblmair M, Becker A, Knez A, Haberl R, Steinbeck G. Pressure-guided nonsurgical myocardial reduction induced by small septal infarctions in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2001;38:846–53.
Sorajja P, Ommen SR, Holmes DR Jr, Dearani JA, Rihal CS, Gersh BJ, Lennon RJ, Nishimura RA. Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2012;126:2374–80.
Olivotto I, Maron BJ, Montereggi A, et al. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1999;33:2044–51.
Sadoul N, Prasad K, Elliott PM, et al. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation. 1997;96:2987–91.
Frenneaux MP, Counihan PJ, Caforio AL, et al. Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation. 1990;82:1995–2002.
Jones S, Elliott PM, Sharma S, McKenna WJ, Whipp BJ. Cardiopulmonary responses to exercise in patients with hypertrophic cardiomyopathy. Heart. 1998;80:60–7.
Chikamori T, Counihan PJ, Doi YL, Takata J, Stewart JT, Frenneaux MP, McKenna WJ. Mechanisms of exercise limitation in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1992;19:507–12.
Maron BJ, Bonow RO, Cannon RO 3rd, Leon MB, Epstein SE. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (2). N Engl J Med. 1987;316:844–52.
Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:2761–96.
van der Lee C, Scholzel B, ten Berg JM, et al. Usefulness of clinical, echocardiographic, and procedural characteristics to predict outcome after percutaneous transluminal septal myocardial ablation. Am J Cardiol. 2008;101:1315–20.
Sherrid MV, Shetty A, Winson G, Kim B, Musat D, Alviar CL, Homel P, Balaram SK, Swistel DG. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamil. Circ Heart Fail. 2013;6:694–702.
Covella M, Rowin EJ, Hill NS, Preston IR, Milan A, Opotowsky AR, Maron BJ, Maron MS, Maron BA. Mechanism of progressive heart failure and significance of pulmonary hypertension in obstructive hypertrophic cardiomyopathy. Circ Heart Fail. 2017;10:e003689.
Nishimura RA, Ommen SR. Hypertrophic cardiomyopathy: the search for obstruction. Circulation. 2006;114:2200–2.
Wigle ED, Sasson Z, Henderson MA, Ruddy TD, Fulop J, Rakowski H, Williams WG. Hypertrophic cardiomyopathy: the importance of the site and the extent of hypertrophy: a review. Prog Cardiovasc Dis. 1985;28:1–83.
Elesber A, Nishimura RA, Rihal CS, Ommen SR, Schaff HV, Holmes DR Jr. Utility of isoproterenol to provoke outflow tract gradients in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2008;101:516–20.
Baim DS. Grossman’s cardiac catheterization, angiography, and intervention. Philadelphia: Lippincott Williams & Wilkins; 2006.
Minakata K, Dearani JA, Nishimura RA, Maron BJ, Danielson GK. Extended septal myectomy for hypertrophic obstructive cardiomyopathy with anomalous mitral papillary muscles or chordae. J Thorac Cardiovasc Surg. 2004;127:481–9.
Klues HG, Roberts WC, Maron BJ. Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy: significance in producing left ventricular outflow obstruction. Circulation. 1991;84:1188–97.
Klues HG, Maron BJ, Dollar AL, Roberts WC. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Circulation. 1992;85:1651–60.
Grigg LE, Wigle ED, Williams WG, et al. Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision making. J Am Coll Cardiol. 1992;20:42–52.
Maron MS, Lesser JR, Maron BJ. Management implications of massive left ventricular hypertrophy in hypertrophic cardiomyopathy significantly underestimated by echocardiography but identified by cardiovascular magnetic resonance. Am J Cardiol. 2010;105:1842–3.
Rickers C, Wilke NM, Jerosch-Herold M, et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation. 2005;112:855–61.
Cooper RM, Binukrishnan SR, Shahzad A, Hasleton J, Sigwart U, Stables RH. Computed tomography angiography planning identifies the target vessel for optimum infarct location and improves clinical outcome in alcohol septal ablation for hypertrophic obstructive cardiomyopathy. EuroIntervention. 2017;12:e2194–203.
Brugada P, Bär FW, de Zwaan C, Roy D, Green M, Wellens HJ. “Sawfish” systolic narrowing of the left anterior descending coronary artery: an angiographic sign of hypertrophic cardiomyopathy. Circulation. 1982;66:800–3.
Maron BJ. Controversies in cardiovascular medicine. Surgical myectomy remains the primary treatment option for severely symptomatic patients with obstructive hypertrophic cardiomyopathy. Circulation. 2007;116:196–206.
Schoendube FA, Klues HG, Reith S, et al. Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus. Circulation. 1995;92(suppl 9):II122–7.
Morrow AG, Brockenbrough EC. Surgical treatment of idiopathic hypertrophic subaortic stenosis: technic and hemodynamic results of subaortic ventriculomyotomy. Ann Surg. 1961;154:181–9.
McIntosh CL, Maron BJ, Cannon RO, Klues HG. Initial results of combined anterior mitral leaflet plication and ventricular septal myotomy-myectomy for relief of left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. Circulation. 1992;86:II60–7.
Kofflard MJ, van Herwerden LA, Waldstein DJ, Ruygrok P, Boersma E, Taams MA, ten Cate FJ. Initial results of combined anterior mitral leaflet extension and myectomy in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 1996;28:197–202.
Hong JH, Schaff HV, Nishimura RA, Abel MD, Dearani JA, Li Z, Ommen SR. Mitral regurgitation in patients with hypertrophic obstructive cardiomyopathy: implications for concomitant valve procedures. J Am Coll Cardiol. 2016;68:1497–504.
Kannappan M, Maron BJ, Rastegar H, Pandian NG, Maron MS, Rowin EJ. Underappreciated occurrence of discrete subaortic membranes producing left ventricular outflow obstruction in hypertrophic cardiomyopathy. Echocardiography. 2017;34:1247–9.
Singh M, Edwards WD, Holmes DR Jr, Tajik AJ, Nishimura RA. Anatomy of the first septal perforating artery: a study with implications for ablation therapy for hypertrophic cardiomyopathy. Mayo Clin Proc. 2001;76:799–802.
Liebregts M, Faber L, Jensen MK, Vriesendorp PA, Januska J, Krejci J, Hansen PR, Seggewiss H, Horstkotte D, Adlova R, Bundgaard H, Ten Berg JM, Veselka J. Outcomes of alcohol septal ablation in younger patients with obstructive hypertrophic cardiomyopathy. JACC Cardiovasc Interv. 2017;10:1134–43.
Liebregts M, Steggerda RC, Vriesendorp PA, van Velzen H, Schinkel AF, Willems R, van Cleemput J, van den Berg MP, Michels M, ten Berg JM. Long-term outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy in the young and the elderly. JACC Cardiovasc Interv. 2016;9:463–9.
Olivotto I, Ommen SR, Maron MS, Cecchi F, Maron BJ. Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Will there ever be a randomized trial? J Am Coll Cardiol. 2007;50:831–4.
Nagueh SF, Ommen SR, Lakkis NM, Killip D, Zoghbi WA, Schaff HV, Danielson GK, Quinones MA, Tajik AJ, Spencer WH. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2001;38:1701–6.
Qin JX, Shiota T, Lever HM, Kapadia SR, Sitges M, Rubin DN, Bauer F, Greenberg NL, Agler DA, Drinko JK, Martin M, Tuzcu EM, Smedira NG, Lytle B, Thomas JD. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol. 2001;38:1994–2000.
Firoozi S, Elliott PM, Sharma S, Murday A, Brecker SJ, Hamid MS, Sachdev B, Thaman R, McKenna WJ. Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. A comparison of clinical, haemodynamic and exercise outcomes. Eur Heart J. 2002;23:1617–24.
Ralph-Edwards A, Woo A, McCrindle BW, Shapero JL, Schwartz L, Rakowski H, Wigle ED, Williams WG. Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score. J Thorac Cardiovasc Surg. 2005;129:351–8.
Ten Cate FJ, Soliman OII, Michels M, Theuns DAMJ, de Jong PL, Geleijnse ML, Serruys PW. Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy. A word of caution. Circ Heart Fail. 2010;3:362–9.
Sorajja P, Valeti U, Nishimura RA, Ommen SR, Rihal CS, Gersh BJ, Hodge DO, Schaff HV, Holmes DR Jr. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2008;118:131–9.
Nagueh SF, Groves BM, Schwartz L, Smith KM, Wang A, Bach RG, Nielsen C, Leya F, Buergler JM, Rowe SK, Woo A, Maldonado YM, Spencer WH 3rd. Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy. A multicenter North American registry. J Am Coll Cardiol. 2011;58:2322–8.
Veselka J, Krejci J, Tomasov P, Zemanek D. Long-term survival after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a comparison with general population. Eur Heart J. 2014;35:2040–5.
Sorajja P, Binder J, Nishimura RA, Holmes DR Jr, Rihal CS, Gersh BJ, Bresnahan JF, Ommen SR. Predictors of an optimal clinical outcome with alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Catheter Cardiovasc Interv. 2013;81:E58–67.
Agarwal S, Tuzcu EM, Desai MY, Smedira N, Lever HM, Lytle BW, Kapadia SR. Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;55:823–34.
Alam M, Dokainish H, Lakkis NM. Hypertrophic obstructive cardiomyopathy-alcohol septal ablation vs. myectomy: a meta-analysis. Eur Heart J. 2009;30:1080–7.
Singh K, Qutub M, Carson K, Hibbert B, Glover C. A meta analysis of current status of alcohol septal ablation and surgical myectomy for obstructive hypertrophic cardiomyopathy. Catheter Cardiovasc Interv. 2016;88:107–15.
Leonardi RA, Kransdorf EP, Simel DL, Wang A. Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment. Circ Cardiovasc Interv. 2010;3:97–104.
McLeod CJ, Ommen SR, Ackerman MJ, et al. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur Heart J. 2007;28:2583–8.
Ball W, Ivanov J, Rakowski H, et al. Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment. J Am Coll Cardiol. 2011;58:2313–21.
Naidu SS. Survival and pacemaker risk after alcohol septal ablation: informing the choice of invasive therapy for hypertrophic cardiomyopathy. Can J Cardiol. 2013;29:1369–70.
Fernandes VL, Nagueh SF, Wang W, Roberts R, Spencer WH 3rd. A prospective follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy — the Baylor experience (1996– 2002). Clin Cardiol. 2005;28(3):124–30.
Veselka J, Lawrenz T, Stellbrink C, Zemanek D, Branny M, Januska J, Groch L, Dimitrow P, Krejci J, Dabrowski M, Mizera S, Kuhn H. Low incidence of procedure-related major adverse cardiac events after alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy. Can J Cardiol. 2013. pii: S0828-282X(13)00263-8.
Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP, Lawrenz T, Boriani G, Estes NAM III, Favale S, Piccininno M, Winters SL, Santini M, Betocchi S, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007;298:405–12.
Kim LK, Swaminathan RV, Looser P, Minutello RM, Wong SC, Bergman G, Naidu SS, Gade CL, Charitakis K, Singh HS, Feldman DN. Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US Nationwide Inpatient Database, 2003-2011. JAMA Cardiol. 2016;1:324–32.
Maron BJ, Yacoub M, Dearani JA. Benefits of surgery in obstructive hypertrophic cardiomyopathy: bring septal myectomy back for European patients. Eur Heart J. 2011;32:1055–8.
Liebregts M, Vriesendorp PA, Mahmoodi BK, Schinkel AF, Michels M, ten Berg JM. A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy. JACC Heart Fail. 2015;3:896–905.
Quintana E, Sabate-Rotes A, Maleszewski JJ, Ommen SR, Nishimura RA, Dearani JA, Schaff HV. Septal myectomy after failed alcohol ablation: does previous percutaneous intervention compromise outcomes of myectomy? J Thorac Cardiovasc Surg. 2015;150:159–67.
Jensen MK, Jacobsson L, Almaas V, van Buuren F, Hansen PR, Hansen TF, Aakhus S, Eriksson MJ, Bundgaard H, Faber L. Influence of septal thickness on the clinical outcome after alcohol septal alation in hypertrophic cardiomyopathy. Circ Cardiovasc Interv. 2016;9:6.
Noseworthy PA, Rosenberg MA, Fifer MA, Palacios IF, Lowry PA, Ruskin JN, Sanborn DM, Picard MH, Vlahakes GJ, Mela T, Das S. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2009;104:128–32.
Maron BJ, Dearani JA, Maron MS, Ommen SR, Rastegar H, Nishimura RA, Swistel DG, Sherrid MV, Ralph-Edwards A, Rakowski H, Smedira NG, Rowin EJ, Desai MY, Lever HM, Spirito P, Ferrazzi P, Schaff HV. Why we need more septal myectomy surgeons: An emerging recognition. J Thorac Cardiovasc Surg. 2017. pii: S0022-5223(17)30123-X. doi:https://doi.org/10.1016/j.jtcvs.2016.12.038. [Epub ahead of print].
Veselka J, Faber L, Liebregts M, Cooper R, Januska J, Krejci J, Bartel T, Dabrowski M, Hansen PR, Almaas VM, Seggewiss H, Horstkotte D, Adlova R, Bundgaard H, Ten Berg J, Stables RH, Jensen MK. Outcome of alcohol septal ablation in mildly symptomatic patients with hypertrophic obstructive cardiomyopathy: a long-term follow-up study based on the Euro-Alcohol Septal Ablation Registry. J Am Heart Assoc. 2017;6:5.
Kovacic JC, Khanna D, Kaplish D, et al. Safety and efficacy of alcohol septal ablation in patients with symptomatic concentric left ventricular hypertrophy and outflow tract obstruction. J Invasive Cardiol. 2010;22:586–91.
Naidu SS. Invasive thoughts: honoring two decades of alcohol septal ablation for hypertrophic cardiomyopathy. J Invasive Cardiol. 2013;25:369–70.
Guerrero M, Wang DD, Himbert D, Urena M, Pursnani A, Kaddissi G, Iyer V, Salinger M, Chakravarty T, Greenbaum A, Makkar R, Vahanian A, Feldman T, O'Neill W. Short-term results of alcohol septal ablation as a bail-out strategy to treat severe left ventricular outflow tract obstruction after transcatheter mitral valve replacement in patients with severe mitral annular calcification. Catheter Cardiovasc Interv. 2017;90:1220–6. https://doi.org/10.1002/ccd.26975.
Gross CM, Schulz-Menger J, Kramer J, Siegel I, Pilz B, Waigand J, Friedrich MG, Uhlich F, Dietz R. Percutaneous transluminal septal artery ablation using polyvinyl alcohol foam particles for septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: acute and 3-year outcomes. J Endovasc Ther. 2004;11:705–11.
Llamas-Esperon GA, Sandoval-Navarrete S. Percutaneous septal ablation with absorbable gelatin sponge in hypertrophic obstructive cardiomyopathy. Catheter Cardiovasc Interv. 2007;69:231–5.
Lafont A, Durand E, Brasselet C, Mousseaux E, Hagege A, Desnos M. Percutaneous transluminal septal coil embolisation as an alternative to alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Heart. 2005;91:92.
Guerrero I, Dhoble A, Fasulo M, Denktas AE, Sami S, Choi S, Balan P, Arain SA, Smalling RW. Safety and efficacy of coil embolization of the septal perforator for septal ablation in patients with hypertrophic obstructive cardiomyopathy. Catheter Cardiovasc Interv. 2016;88:971–7.
Lawrenz T, Kuhn H. Endocardial radiofrequency ablation of septal hypertrophy. A new catheter-based modality of gradient reduction in hypertrophic obstructive cardiomyopathy. Z Kardiol. 2004;93:493–9.
Keane D, Hynes B, King G, Shiels P, Brown A. Feasibility study of percutaneous transvalvular endomyocardial cryoablation for the treatment of hypertrophic obstructive cardiomyopathy. J Invasive Cardiol. 2007;19:247–51.
Cooper RM, Shahzad A, Hasleton J, Digiovanni J, Hall MC, Todd DM, Modi S, Stables RH. Radiofrequency ablation of the interventricular septum to treat outflow tract gradients in hypertrophic obstructive cardiomyopathy: a novel use of CARTOSound® technology to guide ablation. Europace. 2016;18:113–20.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Questions
Questions
-
1.
Septal reduction therapy should be considered for which of the following patients?
-
A.
Patient with severe LV outflow tract obstruction and drug-refractory symptoms, such as severe dyspnea or chest pain (usually NYHA or CCS functional class III/IV), or other important exertional symptoms (e.g., syncope)
-
B.
Patients who are intolerant of optimal medical therapy
-
C.
Patients in whom symptoms are clearly and primarily attributed to obstructive HCM physiology
-
D.
Patients with septal thickness ≥ 15–16 mm at point of septal – mitral contact
-
E.
All of the above
Answer: E. Patients should be considered for septal reduction therapy when (a) symptoms are clearly and primarily attributed to obstructive HCM despite optimal medical therapy; (b) symptoms encompass severe heart failure or angina (NYHA or CCS class III/IV), recurrent obstruction-related syncope, or recurrent clinical decompensation due to refractory paroxysmal atrial fibrillation; (c) a gradient ≥50 mmHg can be demonstrated on optimal medical therapy; and (d) obstruction is clearly dynamic and subvalvular, resulting mainly from septum-to-anterior mitral leaflet contact. Septal wall thickness < 15–16 mm is considered a contraindication to either myectomy or ASA due to the potential risk of septal perforation with creation of a ventricular septal defect.
-
A.
-
2.
The following features would favor the selection of myectomy over alcohol septal ablation as the septal reduction therapy of choice, except:
-
A.
Younger age
-
B.
Septal hypertrophy ≥30 mm
-
C.
Preexisting left bundle branch block
-
D.
Prior cardiac or thoracic surgery
-
E.
Atrial fibrillation that requires a maze procedure
Answer: D. Myectomy surgery is preferred in younger patients; those with massive septal hypertrophy (e.g., ≥30 mm); those with diffuse rather than focal left ventricular hypertrophy that extends to the mid-ventricle or even apex; those with preexisting left bundle branch block (since ASA usually causes right bundle branch block, resulting in a high incidence of complete heart block); those with concomitant cardiac disease requiring surgical intervention: intrinsic severe mitral valve disease, presence of membranes, moderate/severe aortic stenosis, and coronary artery disease favoring coronary artery bypass grafting; and those with atrial fibrillation that might require a maze procedure or left atrium appendage ligation. Prior cardiac or thoracic surgery (given the risks inherent to reoperation) would favor ASA over myectomy.
-
A.
-
3.
The following features would favor the selection of alcohol septal ablation over myectomy as the septal reduction therapy of choice, except:
-
A.
Advanced age
-
B.
Comorbid conditions that would increase surgical risk (e.g., pulmonary hypertension)
-
C.
Presence of pacemaker/ICD
-
D.
Absence or minimal intrinsic disease of mitral valve apparatus and papillary muscles and of other conditions for which cardiac surgery is indicated
-
E.
Preexisting left bundle branch block
Answer: E. Factors that favor ASA over myectomy include advanced age (>65 years), comorbid conditions that would increase surgical risk (e.g., pulmonary hypertension or severe COPD causing significant concerns about lung or airway management), preexisting right bundle branch block (because myectomy usually causes left bundle branch block and a high incidence of complete heart block), presence of pacemaker/ICD that would substantially lower the procedural risk of ASA, prior cardiac or thoracic surgery (given the risks inherent to reoperation), and focal CAD that can be treated with stenting. Myectomy is preferred in those with preexisting left bundle branch block, since ASA usually causes right bundle branch block, resulting in a high incidence of complete heart block.
-
A.
-
4.
In patients being considered for septal reduction therapy, what LV outflow gradient should be demonstrated?
-
A.
LV outflow gradient of ≥30 mmHg with exertion.
-
B.
LV outflow gradient of ≥60 mmHg at rest.
-
C.
LV outflow tract gradient of ≥50 mmHg at rest, with physiologic provocation, or with exertion.
-
D.
No gradient needs to be demonstrated if symptoms of severe heart failure or angina (NYHA or CCS class III/IV) are present.
-
E.
LV outflow tract gradient of ≥60 mmHg at rest, with physiologic provocation, or with exertion.
Answer: C. Candidates for septal reduction therapy must have an LV outflow tract gradient of ≥50 mmHg at rest, with physiologic provocation, or with exertion. While echocardiography is the gold standard, permitting evaluation of obstruction provoked by Valsalva maneuver or treadmill exercise, cardiac catheterization is frequently complementary and often necessary in patients with poor echocardiographic “windows” to evaluate or confirm the severity of LVOT gradient at rest and with provocative maneuvers.
-
A.
-
5.
If a significant resting gradient (gradient of ≥50 mmHg) is not found by echocardiography or during catheterization, the following maneuvers are recommended:
-
A.
Valsalva
-
B.
Induction of an extrasystolic beat to measure the Brockenbrough-Braunwald sign
-
C.
Exercise (e.g., supine bicycle exercise)
-
D.
Pharmacologic challenge (amyl nitrite, nitroglycerine, or isoproterenol)
-
E.
All of the above
Answer: E. If a significant resting gradient (gradient of ≥50 mmHg) is not found during catheterization, provocative maneuvers such as the Valsalva or an induction of an extrasystolic beat to measure the Brockenbrough-Braunwald sign (or a combination of both maneuvers) should then be performed. If a significant gradient is still not provoked, either exercise (e.g., supine bicycle exercise) or pharmacologic challenge (amyl nitrite, nitroglycerine, or isoproterenol) is helpful when the clinical picture strongly suggests obstructive physiology. Isoproterenol hydrochloride provides direct stimulation of the β1- and β2-receptors that simulates exercise and, therefore, may uncover a labile outflow tract gradient.
-
A.
-
6.
Alcohol septal ablation results in the following:
-
A.
Improvement in functional class (NYHA and CCS class)
-
B.
Improvement in peak oxygen consumption
-
C.
Improvement in exercise capacity
-
D.
Improvements in LV synchrony, microvascular function of the subendocardium, and myocardial energetics parameters
-
E.
All of the above
Answer: E. ASA results in a significant improvement in functional class (NYHA and CCS class), peak oxygen consumption , and exercise capacity for up to 8–10 years in published studies. In addition, recent studies have indicated that ASA results in improvements in LV synchrony, microvascular function of the subendocardium, and myocardial energetics parameters. HCM patients after a successful ASA procedure also appear to have long-term survival rates that are comparable to the non-HCM population.
-
A.
-
7.
Selective coronary angiography is required prior to alcohol septal ablation in order to demonstrate or exclude the following findings, except:
-
A.
Exclude concomitant coronary disease.
-
B.
Examine the size of the septal perforator arteries.
-
C.
Exclude collateral circulation from septal branches to other coronary segments.
-
D.
Examine the septal thickness prior to ASA.
-
E.
Examine the distribution of the septal perforator arteries.
Answer: D. Selective coronary angiography should be performed to exclude concomitant coronary disease. Furthermore, in those undergoing workup for septal reduction treatment, the size and distribution of the septal perforator arteries need to be carefully evaluated. In addition, septal arteries may arise from the left main, diagonal branches and even from the right coronary artery, and thus, meticulous angiography in multiple views is imperative. It is also important to exclude the presence of the collateral circulation from septal branches to other coronary segments.
-
A.
-
8.
The following recommendations for septal reduction therapy have been made by the ACCF/AHA 2011 Hypertrophic Cardiomyopathy Guidelines:
-
A.
In those patients who are acceptable surgical candidates, surgical myectomy should generally be preferred (class IIa).
-
B.
In those patients who are acceptable surgical candidates, ASA should be preferred (class IIa).
-
C.
In those patients who are not acceptable candidates for surgical intervention, ASA would be the favored treatment option (class IIb).
-
D.
Patient preference for alcohol septal ablation over surgical myectomy is reasonable after a balanced and thorough discussion (class IIa).
-
E.
All of the above.
Answer: A. ACCF/AHA 2011 Hypertrophic Cardiomyopathy Guidelines recommend that in those patients who are acceptable surgical candidates, surgical myectomy should generally be preferred (class IIa) over ASA (class IIb), whereas in those patients who are not acceptable candidates for surgical intervention, ASA would be the favored treatment option (class IIa). Patient preference for alcohol septal ablation over surgical myectomy is also reasonable after a balanced and thorough discussion (class IIb). An individualized approach to selection of septal reduction therapy is commonly required, with comprehensive assessment of clinical symptoms, associated comorbidities, and echocardiographic and angiographic features that might favor one approach over another.
-
A.
-
9.
When comparing surgical myectomy to ASA, the following statements are correct, except:
-
A.
Myectomy and ASA achieve similar early symptomatic improvements in NYHA heart failure class.
-
B.
More complete gradient reduction may be achieved with myectomy.
-
C.
ASA is associated with higher rate of pacemaker post-ASA.
-
D.
Similar survival rates have been demonstrated when comparing ASA and surgical myectomy in multiple retrospective cohort studies and meta-analyses.
-
E.
A randomized controlled trial comparing ASA to surgical myectomy has demonstrated similar symptomatic improvements in NYHA heart failure class.
Answer: E. The early symptomatic improvements in NYHA heart failure class, syncope, angina, and LV outflow tract gradient have been shown to be similar between myectomy and ASA. There are sufficient data from retrospective cohort studies regarding rates of acute complications, LVOT gradient reduction, and short-term symptomatic improvement; both procedures are similarly efficacious in the modern era. In most reports, more complete gradient reduction is still achieved with surgery, but the magnitude does not translate into clinically meaningful differences in outcomes. ASA still lags behind the ~2–3% rates of pacemaker placement seen with surgery. However, it remains unclear whether this is solely due to the procedure itself or exacerbated by the older age at which patients are preferentially offered alcohol septal ablation. Similar survival rates when comparing ASA and surgical myectomy in multiple retrospective cohort studies and meta-analyses, with follow-up out to 8 years, have been shown. No randomized controlled trials comparing ASA to surgical myectomy have been performed, and it is unlikely that a randomized trial comparing these two therapies in patients with anatomy favorable for both procedures will ever be performed.
-
A.
-
10.
The following factors need to be examined when deciding regarding the appropriateness of the septal reduction therapy, except:
-
A.
Symptoms should be clearly and primarily attributed to obstructive HCM physiology despite optimal medical therapy.
-
B.
Symptoms of severe heart failure or angina.
-
C.
Family history of sudden cardiac death.
-
D.
Gradient ≥50 mmHg should be documented on optimal medical therapy.
-
E.
Obstruction should clearly be subvalvular and dynamic.
Answer: C. Patients should be deemed candidates for isolated septal reduction therapy when (a) symptoms are clearly and primarily attributed to obstructive HCM physiology despite optimal medical therapy; (b) symptoms are severe heart failure or angina (as measured by NYHA or CCS class, respectively), recurrent obstruction-related syncope, or recurrent clinical decompensation due to refractory paroxysmal atrial fibrillation; (c) a gradient ≥50 mmHg can be documented on optimal medical therapy, either at rest or with provocation; and (d) obstruction is clearly subvalvular and dynamic, from septum-to-anterior mitral leaflet contact, and not due to fixed obstructive valvular disease or membranes. Family history of sudden cardiac death should only be a factor in assessing the need for ICD therapy.
-
A.
Rights and permissions
Copyright information
© 2019 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Feldman, D.N., Douglas, J.S., Naidu, S.S. (2019). Indications for and Individualization of Septal Reduction Therapy. In: Naidu, S. (eds) Hypertrophic Cardiomyopathy. Springer, Cham. https://doi.org/10.1007/978-3-319-92423-6_22
Download citation
DOI: https://doi.org/10.1007/978-3-319-92423-6_22
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-92422-9
Online ISBN: 978-3-319-92423-6
eBook Packages: MedicineMedicine (R0)